- Home
- DIBS vs IMUX Comparison
DIBS vs IMUX Comparison
Compare DIBS & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIBS
- IMUX
- Stock Information
- Founded
- DIBS 2000
- IMUX 2016
- Country
- DIBS United States
- IMUX United States
- Employees
- DIBS 284
- IMUX N/A
- Industry
- DIBS Catalog/Specialty Distribution
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- DIBS Consumer Discretionary
- IMUX Health Care
- Exchange
- DIBS Nasdaq
- IMUX Nasdaq
- Market Cap
- DIBS 101.5M
- IMUX 90.4M
- IPO Year
- DIBS 2021
- IMUX N/A
- Fundamental
- Price
- DIBS $2.80
- IMUX $0.79
- Analyst Decision
- DIBS Hold
- IMUX Strong Buy
- Analyst Count
- DIBS 1
- IMUX 5
- Target Price
- DIBS N/A
- IMUX $7.50
- AVG Volume (30 Days)
- DIBS 49.1K
- IMUX 1.3M
- Earning Date
- DIBS 11-07-2025
- IMUX 11-06-2025
- Dividend Yield
- DIBS N/A
- IMUX N/A
- EPS Growth
- DIBS N/A
- IMUX N/A
- EPS
- DIBS N/A
- IMUX N/A
- Revenue
- DIBS $88,640,000.00
- IMUX N/A
- Revenue This Year
- DIBS $3.69
- IMUX N/A
- Revenue Next Year
- DIBS $6.79
- IMUX N/A
- P/E Ratio
- DIBS N/A
- IMUX N/A
- Revenue Growth
- DIBS 3.21
- IMUX N/A
- 52 Week Low
- DIBS $2.30
- IMUX $0.56
- 52 Week High
- DIBS $5.00
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- DIBS 56.46
- IMUX 42.07
- Support Level
- DIBS $2.68
- IMUX $0.74
- Resistance Level
- DIBS $2.90
- IMUX $0.90
- Average True Range (ATR)
- DIBS 0.11
- IMUX 0.06
- MACD
- DIBS 0.01
- IMUX -0.00
- Stochastic Oscillator
- DIBS 64.29
- IMUX 25.02
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The Company has a single reportable and operating segment that contains one reporting unit, which consists of the Company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.